Utah Cancer Specialists

Last Updated November 1, 2019
Protocol Number Indication Protocol NCT number
STA004 Advanced Solid Tumor A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of a Drug in Patients with Advanced Solid Tumors. NCT03416816
STA002 Advanced Solid Tumor A Phase 1 Study For Study Participants With BRAFF V-600 Mutation In Melanoma  Or Other Solid Tumors NCT03864042
#BRE004 Breast A Phase 1a/1b Study of an Antibody, in Patients with Advanced Solid Tumors NCT03514121
BRE005 Breast A Phase 3 Open-Label, Randomized,  Study of a Drug versus Treatment of Physician’s Choice  in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated NCT02915744
BRE006 Breast A phase 3,  Randomized, Open-Label Trial to Evaluate Efficacy and Safety of a Drug with Endocrine Therapy as Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer NCT03701334
BRE007 Breast A phase II trial to compare efficacy of Study Drug in combination with Everolimus and Exemestane versus Everolimus and Exemestane in Post-Menopausal Women with HR+ / HER2- Metastatic Breast Cancer NCT03659136
BRE008 Breast  A Phase 3 Randomized, Open-Label, Active – Controlled, Multicenter Trial Emerald Study Drug VS. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy NCT03778931
BRE009 Breast A Phase III Randomised Study Assessing the Efficacy and Safety of Study Drug+ Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Locally Advanced (Inoperable) or Metastatic ER PR negative HER2+ Triple Negative Breast Cancer NCT03997123
BRE010 Breast A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer NCT03961698
#ENDO001 Endometrial A Phase 1a/1b Study of  an  Antibody, in Patients with Advanced Solid Tumors NCT03514121
GAS001 Gastric A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating  a drug  in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer NCT03694522
LUN002 Lung NSCLC A Randomized, Double-Blind, Phase 3 Study of chemptherapy  with or without a drug in EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) NCT03515837
LUN003 Lung NSCLC A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of a Drug + Standard Therapy + a Study Drug with or without a drug as First-lineTreatment in Participants with Metastatic Nonsquamous NSCLC NCT03829319
LYM003 Lymphoma A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Drug in Combination with Standard Therapy in Patients with Relapsed Indolent B-Cell con-Hodgkin’s Lymphoma (iNHL). NCT02367040
MDS001 MDS Low Risk A Phase3,Open-Label,Randomized Study to Compare the Efficiency and Safety of Luspatercept versus Epoetin ALFA for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk MDS in ESA Naïve Subjects who Require Red Blood Cell Transfusions NCT03682536
MM001 Multiple Myeloma A Phase 2 Study to Evaluate Subcutaneous Study Drug in Combination with Standard Multiple Myeloma Treatment Regimens NCT03412565
#OVA004 Ovarian A Phase 1a/1b Study of an  Antibody, in Patients with Previously Treated Ovarian Cancer NCT03514121
OVA005 Ovarian A Randomized, Double-Blind, Phase 3 Study Comparison of Platinum-Based Therapy with Two Drugs Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III of IV Nonmucinous Epithelial Ovarian Cancer NCT03602859
PRO002 Prostate A Phase 1b-2 Study of a Drug in Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT03431350
PRO003 Prostate A Phase 3 Randomized, Placebo-controlled, Double-blind Study of a Drug in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Predisone for Treatment of Subjects with Metastatic Prostate Cancer NCT03748641
REN001 Renal A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Renal Cell Carcinoma NCT03961698